Integration of Liquid Biopsies in Clinical Management of Metastatic Prostate Cancer

Overview

Journal Curr Oncol Rep

Publisher Current Science

Specialty Oncology

Date 2022 May 16

PMID 35575959

Authors

Varsha Tulpule

Gareth J Morrison

Mary Falcone

David I Quinn

Amir Goldkorn

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: The field of liquid biopsies is constantly evolving through novel technologies. This review outlines current data on liquid biopsies and application to clinical management of metastatic prostate cancer.

Recent Findings: To date, there are three platforms with FDA approval for use in the setting of metastatic prostate cancer and others which have been clinically validated. There is substantial evidence supporting the use of circulating tumor cell (CTC) enumeration to guide prognosis in metastatic castration-resistant prostate cancer (mCRPC). Additional evidence supports targeted sequencing of CTC and cell-free DNA (cfDNA) to guide androgren-directed therapy, identify candidates for treatment with PARP inhibitors, and monitor development of resistance. As a real-time and minimally invasive approach, utilization of liquid biopsies has the potential to drastically impact the treatment of metastatic prostate cancer and improve overall survival. With further clinical validation, additional liquid biopsy is likely to enter standard clinical practice.

Citing Articles

Prognostic Role of Prostate-specific Antigen Isoforms and Their Early Kinetics in Patients With Metastatic Castration-resistant Prostate Cancer Receiving New Generation Androgen Receptor Targeted Agents.

Fiala O, Hosek P, Korunkova H, Tkadlecova M, Hora M, Sikova D In Vivo. 2025; 39(2):859-869.

PMID: 40010964 PMC: 11884487. DOI: 10.21873/invivo.13889.

Circulating Tumor Cell Count and Overall Survival in Patients With Metastatic Hormone-Sensitive Prostate Cancer.

Goldkorn A, Tangen C, Plets M, Bsteh D, Xu T, Pinski J JAMA Netw Open. 2024; 7(10):e2437871.

PMID: 39374015 PMC: 11581504. DOI: 10.1001/jamanetworkopen.2024.37871.

Castration-resistant prostate cancer monitoring by cell-free circulating biomarkers.

Chrenkova E, Studentova H, Hola K, Kahounova Z, Hendrychova R, Soucek K Front Oncol. 2024; 14:1394292.

PMID: 39319053 PMC: 11420116. DOI: 10.3389/fonc.2024.1394292.

Liquid Biopsy in the Clinical Management of Cancers.

Ho H, Chung K, Kan C, Wong S Int J Mol Sci. 2024; 25(16).

PMID: 39201281 PMC: 11354853. DOI: 10.3390/ijms25168594.

Bioprinted research models of urological malignancy.

Wang G, Mao X, Wang W, Wang X, Li S, Wang Z Exploration (Beijing). 2024; 4(4):20230126.

PMID: 39175884 PMC: 11335473. DOI: 10.1002/EXP.20230126.

References

Vagner T, Spinelli C, Minciacchi V, Balaj L, Zandian M, Conley A . Large extracellular vesicles carry most of the tumour DNA circulating in prostate cancer patient plasma. J Extracell Vesicles. 2018; 7(1):1505403. PMC: 6084494. DOI: 10.1080/20013078.2018.1505403. View

Soekmadji C, Corcoran N, Oleinikova I, Jovanovic L, Ramm G, Nelson C . Extracellular vesicles for personalized therapy decision support in advanced metastatic cancers and its potential impact for prostate cancer. Prostate. 2017; 77(14):1416-1423. DOI: 10.1002/pros.23403. View

Wu A, Cremaschi P, Wetterskog D, Conteduca V, Franceschini G, Kleftogiannis D . Genome-wide plasma DNA methylation features of metastatic prostate cancer. J Clin Invest. 2020; 130(4):1991-2000. PMC: 7108919. DOI: 10.1172/JCI130887. View

Conteduca V, Wetterskog D, Sharabiani M, Grande E, Fernandez-Perez M, Jayaram A . Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study. Ann Oncol. 2017; 28(7):1508-1516. PMC: 5834043. DOI: 10.1093/annonc/mdx155. View

Goldkorn A, Tangen C, Plets M, Morrison G, Cunha A, Xu T . Baseline Circulating Tumor Cell Count as a Prognostic Marker of PSA Response and Disease Progression in Metastatic Castrate-Sensitive Prostate Cancer (SWOG S1216). Clin Cancer Res. 2021; 27(7):1967-1973. PMC: 8026618. DOI: 10.1158/1078-0432.CCR-20-3587. View

Teo M, Rathkopf D, Kantoff P . Treatment of Advanced Prostate Cancer. Annu Rev Med. 2019; 70:479-499. PMC: 6441973. DOI: 10.1146/annurev-med-051517-011947. View

Silva R, Moran B, Baird A, ORourke C, Finn S, McDermott R . Longitudinal analysis of individual cfDNA methylome patterns in metastatic prostate cancer. Clin Epigenetics. 2021; 13(1):168. PMC: 8403420. DOI: 10.1186/s13148-021-01155-w. View

Taavitsainen S, Annala M, Ledet E, Beja K, Miller P, Moses M . Evaluation of Commercial Circulating Tumor DNA Test in Metastatic Prostate Cancer. JCO Precis Oncol. 2020; 3. PMC: 7446428. DOI: 10.1200/PO.19.00014. View

Scher H, Heller G, Molina A, Attard G, Danila D, Jia X . Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer. J Clin Oncol. 2015; 33(12):1348-55. PMC: 4397279. DOI: 10.1200/JCO.2014.55.3487. View

10.

Hindson B, Ness K, Masquelier D, Belgrader P, Heredia N, Makarewicz A . High-throughput droplet digital PCR system for absolute quantitation of DNA copy number. Anal Chem. 2011; 83(22):8604-10. PMC: 3216358. DOI: 10.1021/ac202028g. View

11.

Cristofanilli M, Budd G, Ellis M, Stopeck A, Matera J, Miller M . Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004; 351(8):781-91. DOI: 10.1056/NEJMoa040766. View

12.

Robinson D, Van Allen E, Wu Y, Schultz N, Lonigro R, Mosquera J . Integrative clinical genomics of advanced prostate cancer. Cell. 2015; 161(5):1215-1228. PMC: 4484602. DOI: 10.1016/j.cell.2015.05.001. View

13.

Herberts C, Murtha A, Fu S, Wang G, Schonlau E, Xue H . Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer. Eur Urol. 2020; 78(6):834-844. DOI: 10.1016/j.eururo.2020.04.058. View

14.

Adams D, Stefansson S, Haudenschild C, Martin S, Charpentier M, Chumsri S . Cytometric characterization of circulating tumor cells captured by microfiltration and their correlation to the CellSearch(®) CTC test. Cytometry A. 2014; 87(2):137-44. DOI: 10.1002/cyto.a.22613. View

15.

de Bono J, Scher H, Montgomery R, Parker C, Miller M, Tissing H . Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008; 14(19):6302-9. DOI: 10.1158/1078-0432.CCR-08-0872. View

16.

Yu E, Li H, Higano C, Agarwal N, Pal S, Alva A . SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol. 2015; 33(14):1601-8. PMC: 4417730. DOI: 10.1200/JCO.2014.59.4127. View

17.

Hussain M, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S . Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2020; 383(24):2345-2357. DOI: 10.1056/NEJMoa2022485. View

18.

Shaffer D, Leversha M, Danila D, Lin O, Gonzalez-Espinoza R, Gu B . Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. Clin Cancer Res. 2007; 13(7):2023-9. DOI: 10.1158/1078-0432.CCR-06-2701. View

19.

Graf R, Hullings M, Barnett E, Carbone E, Dittamore R, Scher H . Clinical Utility of the Nuclear-localized AR-V7 Biomarker in Circulating Tumor Cells in Improving Physician Treatment Choice in Castration-resistant Prostate Cancer. Eur Urol. 2019; 77(2):170-177. PMC: 7472426. DOI: 10.1016/j.eururo.2019.08.020. View

20.

Lord C, Ashworth A . PARP inhibitors: Synthetic lethality in the clinic. Science. 2017; 355(6330):1152-1158. PMC: 6175050. DOI: 10.1126/science.aam7344. View